. "55191" . . . . . "437181944"^^ . . . . . . "Gepirone is an antidepressant and anxiolytic drug of the azapirone group that was synthesized by Bristol-Myers Squibb in 1986 and has been under development for the treatment of depression but has yet to be marketed. It has been under development in the U.S. in an extended release form (referred to as gepirone ER), but despite completing phase III clinical trials and demonstrating efficacy, it has been rejected multiple times by the Food and Drug Administration (FDA) during the drug approval process. However, in March 2016, the FDA reversed course and ruled favorably on the efficacy of gepirone."@en . . . . "changed"@en . . "BMY-13805, MJ-13805, ORG-13011; Ariza, Variza, Velexity"@en . "\u30B2\u30D4\u30ED\u30F3(Gepirone)\u306F\u3001\u7CFB\u306E\u6297\u3046\u3064\u85AC\u3001\u6297\u4E0D\u5B89\u85AC\u3067\u3042\u308B\u3002\u30A2\u30B6\u30D4\u30ED\u30F3\u7CFB\u306E\u4ED6\u306E\u85AC\u5264\u3068\u6BD4\u3079\u30015-HT1A\u53D7\u5BB9\u4F53\u306E\u9078\u629E\u7684\u30D1\u30FC\u30B7\u30E3\u30EB\u30A2\u30B4\u30CB\u30B9\u30C8\u3068\u3057\u3066\u4F5C\u7528\u3059\u308B\u3002\u30A2\u30E1\u30EA\u30AB\u5408\u8846\u56FD\u3067\u958B\u767A\u3055\u308C\u305F\u304C\u3001\u7B2C\u4E09\u76F8\u306E\u81E8\u5E8A\u8A66\u9A13\u3092\u30AF\u30EA\u30A2\u3067\u304D\u305A\u3001\u627F\u8A8D\u3055\u308C\u306A\u304B\u3063\u305F\u3002\u305D\u306E\u7D50\u679C\u3001\u5546\u6A19\u540D\u307E\u3067\u6C7A\u307E\u3063\u3066\u3044\u305F\u3082\u306E\u306E\u3001\u30B2\u30D4\u30ED\u30F3\u306F\u5E02\u5834\u306B\u306F\u51FA\u3055\u308C\u306A\u304B\u3063\u305F\u3002 \u30B2\u30D4\u30ED\u30F3\u306F\u3001\u30D6\u30EA\u30B9\u30C8\u30EB\u30FB\u30DE\u30A4\u30E4\u30FC\u30BA \u30B9\u30AF\u30A4\u30D6\u304C\u958B\u767A\u3057\u305F\u304C\u30011993\u5E74\u306BFabre-Kramer\u306B\u30E9\u30A4\u30BB\u30F3\u30B9\u3055\u308C\u305F\u3002\u30A2\u30E1\u30EA\u30AB\u98DF\u54C1\u533B\u85AC\u54C1\u5C40(FDA)\u306F\u30B2\u30D4\u30ED\u30F3\u306E\u627F\u8A8D\u30922004\u5E74\u306B\u62D2\u7D76\u3057\u305F\u30022007\u5E745\u6708\u306B\u306F\u3001FDA\u304C2004\u5E74\u306B\u8981\u8ACB\u3057\u305F\u8FFD\u52A0\u306E\u66F8\u985E\u3092\u6DFB\u3048\u3066\u3001\u518D\u3073\u4E8B\u524D\u767B\u9332\u306E\u7533\u8ACB\u304C\u306A\u3055\u308C\u305F\u304C\u3001\u518D\u3073\u62D2\u7D76\u3055\u308C\u305F\u3002"@ja . . . . . "19"^^ . "11584979"^^ . . . . . . . . "250"^^ . "2"^^ . "\u30B2\u30D4\u30ED\u30F3(Gepirone)\u306F\u3001\u7CFB\u306E\u6297\u3046\u3064\u85AC\u3001\u6297\u4E0D\u5B89\u85AC\u3067\u3042\u308B\u3002\u30A2\u30B6\u30D4\u30ED\u30F3\u7CFB\u306E\u4ED6\u306E\u85AC\u5264\u3068\u6BD4\u3079\u30015-HT1A\u53D7\u5BB9\u4F53\u306E\u9078\u629E\u7684\u30D1\u30FC\u30B7\u30E3\u30EB\u30A2\u30B4\u30CB\u30B9\u30C8\u3068\u3057\u3066\u4F5C\u7528\u3059\u308B\u3002\u30A2\u30E1\u30EA\u30AB\u5408\u8846\u56FD\u3067\u958B\u767A\u3055\u308C\u305F\u304C\u3001\u7B2C\u4E09\u76F8\u306E\u81E8\u5E8A\u8A66\u9A13\u3092\u30AF\u30EA\u30A2\u3067\u304D\u305A\u3001\u627F\u8A8D\u3055\u308C\u306A\u304B\u3063\u305F\u3002\u305D\u306E\u7D50\u679C\u3001\u5546\u6A19\u540D\u307E\u3067\u6C7A\u307E\u3063\u3066\u3044\u305F\u3082\u306E\u306E\u3001\u30B2\u30D4\u30ED\u30F3\u306F\u5E02\u5834\u306B\u306F\u51FA\u3055\u308C\u306A\u304B\u3063\u305F\u3002 \u30B2\u30D4\u30ED\u30F3\u306F\u3001\u30D6\u30EA\u30B9\u30C8\u30EB\u30FB\u30DE\u30A4\u30E4\u30FC\u30BA \u30B9\u30AF\u30A4\u30D6\u304C\u958B\u767A\u3057\u305F\u304C\u30011993\u5E74\u306BFabre-Kramer\u306B\u30E9\u30A4\u30BB\u30F3\u30B9\u3055\u308C\u305F\u3002\u30A2\u30E1\u30EA\u30AB\u98DF\u54C1\u533B\u85AC\u54C1\u5C40(FDA)\u306F\u30B2\u30D4\u30ED\u30F3\u306E\u627F\u8A8D\u30922004\u5E74\u306B\u62D2\u7D76\u3057\u305F\u30022007\u5E745\u6708\u306B\u306F\u3001FDA\u304C2004\u5E74\u306B\u8981\u8ACB\u3057\u305F\u8FFD\u52A0\u306E\u66F8\u985E\u3092\u6DFB\u3048\u3066\u3001\u518D\u3073\u4E8B\u524D\u767B\u9332\u306E\u7533\u8ACB\u304C\u306A\u3055\u308C\u305F\u304C\u3001\u518D\u3073\u62D2\u7D76\u3055\u308C\u305F\u3002"@ja . . "7372"^^ . . "5"^^ . . . . . "QOIGKGMMAGJZNZ-UHFFFAOYSA-N"@en . "49836"^^ . . "29"^^ . . . . . . . . . "1045881563"^^ . . "284092" . . "N06"@en . . . . "55191"^^ . . . . . "Gepirona \u00E9 um antidepressivo e ansiol\u00EDtico da classe das azapironas. Foi sintetizado por Bristol-Myers Squibb em 1986 e tem sido estudado para o tratamento da depress\u00E3o, mas ainda n\u00E3o \u00E9 comercializado. O f\u00E1rmaco est\u00E1 em desenvolvimento nos EUA em uma forma de libera\u00E7\u00E3o prolongada, mas apesar de completar os ensaios cl\u00EDnicos de fase III e demonstrar efic\u00E1cia, foi rejeitado v\u00E1rias vezes pela Food and Drug Administration (FDA). No entanto, em mar\u00E7o de 2016, o FDA posicionou-se favoravelmente sobre a efic\u00E1cia da gepirona."@pt . . "gepirone hydrochloride"@en . . "284092"^^ . . . . . . . . . . "83928-76-1" . "JW5Y7B8Z18"@en . . "-10800.0"^^ . . . . "O=C1NCCCCN3CCNCC3"@en . . . . . . . "Gepirona \u00E9 um antidepressivo e ansiol\u00EDtico da classe das azapironas. Foi sintetizado por Bristol-Myers Squibb em 1986 e tem sido estudado para o tratamento da depress\u00E3o, mas ainda n\u00E3o \u00E9 comercializado. O f\u00E1rmaco est\u00E1 em desenvolvimento nos EUA em uma forma de libera\u00E7\u00E3o prolongada, mas apesar de completar os ensaios cl\u00EDnicos de fase III e demonstrar efic\u00E1cia, foi rejeitado v\u00E1rias vezes pela Food and Drug Administration (FDA). No entanto, em mar\u00E7o de 2016, o FDA posicionou-se favoravelmente sobre a efic\u00E1cia da gepirona. Al\u00E9m de suas propriedades antidepressivas e ansiol\u00EDticas, constatou-se que a gepirona melhora os sintomas de disfun\u00E7\u00E3o sexual em homens e mulheres. Os efeitos pr\u00F3-sexuais parecem ser independentes de seus efeitos antidepressivos e ansiol\u00EDticos."@pt . . "83928"^^ . "AX19"@en . "Gepirona"@pt . . . . . "Gepirone"@en . . . . . . . . . . . . . . "1"^^ . . . "Gepirone is an antidepressant and anxiolytic drug of the azapirone group that was synthesized by Bristol-Myers Squibb in 1986 and has been under development for the treatment of depression but has yet to be marketed. It has been under development in the U.S. in an extended release form (referred to as gepirone ER), but despite completing phase III clinical trials and demonstrating efficacy, it has been rejected multiple times by the Food and Drug Administration (FDA) during the drug approval process. However, in March 2016, the FDA reversed course and ruled favorably on the efficacy of gepirone. In addition to its antidepressant and anxiolytic properties, gepirone has been found to improve symptoms of sexual dysfunction in men and women. Moreover, the pro-sexual effects appear to be independent of its antidepressant and anxiolytic effects."@en . . . . . . "44"^^ . . . . . "\u30B2\u30D4\u30ED\u30F3"@ja . . . . . "JW5Y7B8Z18" .